2 Result: Nasdaq:TARS
Buy Ratings: TARS, VICR, SNDX, ENLC, AMZN, UFPT, PEN - Key Upside Potential
June 26th, 2023
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company specializing in ophthalmic therapeutics, has been maintained at a Buy rating by HC Wainwright & Co., who raised the price target from $40 to $44. $TARS closed at $17.15. Read more
Market Buzz: Bullish Narrative for Liquid Media, Tarsus Pharma, Vertiv, and Neogen
June 17th, 2023
Shares of Liquid Media Group Ltd. (Nasdaq: YVR) experienced a notable surge of over 11% in after-hours trading Friday as the company revealed the sale of its wholly-owned subsidiary, IndieFlix Group, for a total purchase price of US$1.2 million. T. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login